[1]胡欣,李兴佳,韩雪,等.垂体意外瘤的临床诊治:共识与争议[J].国际内分泌代谢杂志,2023,43(04):361-364.[doi:10.3760/cma.j.cn121383-20220126-01050]
　Hu Xin,Li Xingjia,Han Xue,et al.Pituitary incidentaloma: consensus and controversies[J].International Journal of Endocrinology and Metabolism,2023,43(04):361-364.[doi:10.3760/cma.j.cn121383-20220126-01050]
点击复制

垂体意外瘤的临床诊治:共识与争议()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
43
期数:
2023年04期
页码:
361-364
栏目:
指南与共识
出版日期:
2023-07-20

文章信息/Info

Title:
Pituitary incidentaloma: consensus and controversies
作者:
胡欣1; 李兴佳2; 韩雪1; 何志伟1; 刘超1; 2
1南京中医药大学附属中西医结合医院内分泌科,南京 210028; 2江苏省中医药研究院瘿病证治重点研究室,南京 210028
Author(s):
Hu Xin;  Li Xingjia;  Han Xue;  He Zhiwei;  Liu Chao
Department of Endocrinology, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210028, China; Key Laboratory of TCM Syndrome & Treatment of Yingbing of State Administration of Traditional Chinese Medicine, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing 210028, China
关键词:
垂体意外瘤;  初始评估;  随访观察;  治疗措施
Keywords:
Pituitary incidentaloma;  Inital evaluation;  Follow-up;  Treatment
DOI:
10.3760/cma.j.cn121383-20220126-01050
摘要:
垂体意外瘤(PI)是指由于垂体以外的疾病行影像学检查而意外发现的垂体病变。随着近年来影像学技术的飞速发展与广泛应用,PI的检出率逐年递增。虽然多数PI为无功能垂体腺瘤,但随着病灶体积的增长,其可能侵及垂体与邻近结构从而导致垂体功能减退和(或)视力障碍,而功能性垂体瘤过量分泌相应激素可对全身各系统造成危害。然而,全球范围内对PI的管理缺乏重视,难以形成规范的诊疗策略,进而造成误诊误治率显著增加。尽管国内外已颁布PI指南与共识,但在初始评估、随访观察、手术指征、药物干预及放射治疗等方面仍存在诸多争议。
Abstract:
Pituitary incidentaloma(PI)refers to the lesions of the pituitary region discovered fortuitously by imaging for reasons unrelated to pituitary disease. In recent years, improvements in the quality and availability of radiological examinations leads to an increase in the discovery of PI. Most PIs are non-functioning pituitary adenomas, but the tumors eventually grow to provoke hypopituitarism and/or visual disturbances, and excess hormones secreted by functional pituitary adenoma do harm to the whole body. However, due to the lack of standardized PI management globally, it is challenging to develop an uniform diagnosis and strategy, leading to an uptick in misdiagnosis and mistreatment. Although PI guidelines and consensus have been issued at home and abroad, there are still controversies in initial evaluation, follow-up, surgical indications, medication and radiotherapy.

参考文献/References:

[1] Constantinescu SM,Maiter D.Pituitary incidentaloma[J].Presse Med,2021,50(4):104081.DOI:10.1016/j.lpm.2021.104081.
[2] Freda PU,Beckers AM,Katznelson L,et al.Pituitary incidentaloma:an endocrine society clinical practice guideline[J].J Clin Endocrinol Metab,2011,96(4):894-904.DOI:10.1210/jc.2010-1048.
[3] Molitch ME.Diagnosis and treatment of pituitary adenomas:a review[J].JAMA,2017,317(5):516-524.DOI:10.1001/jama.2016.19699.
[4] Toini A,Dolci A,Ferrante E,et al.Screening for ACTH-dependent hypercortisolism in patients affected with pituitary incidentaloma[J].Eur J Endocrinol,2015,172(4):363-369.DOI:10.1530/EJE-14-0599.
[5] Torpy DJ.Screening for ACTH-dependent hypercortisolism in patients with pituitary incidentaloma[J].Eur J Endocrinol,2015,172(4):C1-4.DOI:10.1530/EJE-15-0058.
[6] Karavitaki N,Collison K,Halliday J,et al.What is the natural history of nonoperated nonfunctioning pituitary adenomas?[J].Clin Endocrinol(Oxf),2007,67(6):938-943.DOI:10.1111/j.1365-2265.2007.02990.x.
[7] Carosi G,Malchiodi E,Ferrante E,et al.Hypothalamic-pituitary axis in non-functioning pituitary adenomas:focus on the prevalence of isolated central hypoadrenalism[J].Neuroendocrinology,2015,102(4):267-273.DOI:10.1159/000430815.
[8] Boguszewski CL,de Castro Musolino NR,Kasuki L.Management of pituitary incidentaloma[J].Best Pract Res Clin Endocrinol Metab,2019,33(2):101268.DOI:10.1016/j.beem.2019.04.002.
[9] Tresoldi AS,Carosi G,Betella N,et al.Clinically nonfunctioning pituitary incidentalomas:characteristics and natural history[J].Neuroendocrinology,2020,110(7-8):595-603.DOI:10.1159/000503256.
[10] Iglesias P,Arcano K,Triviño V,et al.Giant non-functioning pituitary adenoma:clinical characteristics and therapeutic outcomes[J].Exp Clin Endocrinol Diabetes,2021,129(4):309-313.DOI:10.1055/a-1017-3288.
[11] Bonomo G,Bertani GA,Carrabba GG,et al.The suprasellar volume of nonfunctioning pituitary adenomas:a useful tool for predicting visual field deficits[J].Pituitary,2020,23(5):552-557.DOI:10.1007/s11102-020-01060-0.
[12] Han AJ,Varlamov EV,Fleseriu M.Nonfunctioning pituitary microadenomas,should imaging interval be extended? A large single-center cohort study[J].J Clin Endocrinol Metab,2022,107(3):e1231-e1241.DOI:10.1210/clinem/dgab748.
[13] Morinaga Y,Abe I,Nii K,et al.Characteristics and clinical outcomes in pituitary incidentalomas and non-incidental pituitary tumors treated with endoscopic transsphenoidal surgery[J].Medicine(Baltimore),2020,99(44):e22713.DOI:10.1097/MD.0000000000022713.
[14] Losa M,Donofrio CA,Barzaghi R,et al.Presentation and surgical results of incidentally discovered nonfunctioning pituitary adenomas:evidence for a better outcome independently of other patients' characteristics[J].Eur J Endocrinol,2013,169(6):735-742.DOI:10.1530/EJE-13-0515.
[15] Vieira Neto L,Wildemberg LE,Moraes AB,et al.Dopamine receptor subtype 2 expression profile in nonfunctioning pituitary adenomas and in vivo response to cabergoline therapy[J].Clin Endocrinol(Oxf),2015,82(5):739-746.DOI:10.1111/cen.12684.
[16] Greenman Y,Cooper O,Yaish I,et al.Treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists[J].Eur J Endocrinol,2016,175(1):63-72.DOI:10.1530/EJE-16-0206.
[17] Fusco A,Giampietro A,Bianchi A,et al.Treatment with octreotide LAR in clinically non-functioning pituitary adenoma:results from a case-control study[J].Pituitary,2012,15(4):571-578.DOI:10.1007/s11102-011-0370-8.
[18] Raverot G,Burman P,McCormack A,et al.European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas[J].Eur J Endocrinol,2018,178(1):G1-G24.DOI:10.1530/EJE-17-0796.
[19] Lasolle H,Cortet C,Castinetti F,et al.Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas[J].Eur J Endocrinol,2017,176(6):769-777.DOI:10.1530/EJE-16-0979.
[20] Plitt AR,El Ahmadieh TY,Aoun SG,et al.Fractionated cyberKnife stereotactic radiotherapy for perioptic pituitary adenomas[J].World Neurosurg,2019,126:e1359-e1364.DOI:10.1016/j.wneu.2019.03.102.
[21] Barber SM,Teh BS,Baskin DS.Fractionated stereotactic radiotherapy for pituitary adenomas:single-center experience in 75 consecutive patients[J].Neurosurgery,2016,79(3):406-417.DOI:10.1227/NEU.0000000000001155.

备注/Memo

备注/Memo:
基金项目:国家自然科学基金项目(82205050)
通信作者：刘超，Email: liuchao@nfmcn.com
更新日期/Last Update: 2023-08-15